Cetuximab biweekly (q2w) plus mFOLFOX6 as 1st line therapy in patients (pts) with KRAS wild-type (wt) (exon 2) metastatic colorectal cancer (mCRC) – Primary endpoint and subgroup analysis of the CEBIFOX trial

Authors :: Tanja Trarbach
Thomas Herold
Gabriele Linden
Saskia Ting
Karl Worm
Karina Kostbade
Peter Markus
Johannes Meiler
Brigitte Schumacher
Heike Knipp
Stefan Kasper
H.T. Steinmetz
Peter Reimer
Martin Schuler
T. Höhler
Kurt Werner Schmid
Winfried Berger
Andreas Paul
Alexander Dechêne
Source :: Annals of Oncology. 27:vi167
Publication Year :: 2016
Publisher :: Elsevier BV, 2016.

Full Text Access

Tools